2010年3月出版的国际xx《血液》杂志刊发了哈尔滨医科大学附属{dy}临床医学院周晋教授率领的课题组一项课题——《单一应用亚砷酸xx初发性儿童急性早幼粒细胞的研究》。
该课题组首次证实，单用亚砷酸可使患儿M3型白血病病情xx缓解率显著提高，与目前公认的维甲酸联合蒽环类xxx方案疗效相当，且不存在明显的慢性砷中毒及继发肿瘤的风险。
哈医大附属一院博士生导师、血液科主任周晋教授等人于2002年起立项攻关，在国内首次着手评估单用亚砷酸对儿童APL的有效性和安全性。他们在临床中筛选出19名4—15岁的初发性APL患儿，对4—6岁及6岁以上者，每日静点亚砷酸0.16—0.2毫克/公斤，每日{zd0}剂量为10毫克。每日输注亚砷酸直至患者达到血液学症状xx缓解，或{zd0}剂量为60个剂量。在这些患儿中，血液学xx缓解率为89.5%，达到xx缓解率的平均时间大约为38天；达xx缓解率的亚砷酸累积剂量为6.1毫克/公斤。
本项xxxx随访一直持续到2008年12月底，其中17例儿童xx缓解，2例死于早期颅内出血，5年总体存活率和无病存活率分别为83.9%和72.2%。尽管每例病人定期应用亚砷酸xx持续时间3年多，但在用药期结束后，对部分病例进行尿液、指甲和毛发浓度测定，在停药24个月以上者，未见严重的慢性砷中毒表现，也未有皮肤癌、肺癌及膀胱癌等继发肿瘤的发生。
专家评价指出，此项研究结果表明，单用亚砷酸xx初发性儿童M3型白血病患者，具有高效低毒及不易耐药的优势，其疗效等同于经典的维甲酸联合蒽环类xxx的化疗方案。(Bioon.com)
生物谷推荐原文出处：
Blood
Single-agent arsenic trioxide in the
treatment of children with newly diagnosed acute promyelocytic
leukemia
Jin Zhou1, Yingmei Zhang2, Jinmei Li1, Xiaoxia Li1, Jinxiao Hou1,
Yanqiu Zhao1, Xiuhua Liu2, Xueying Han1, Longhu Hu1, Shuye Wang1,
Yanhong Zhao1, Ying Zhang1, Shengjin Fan1, Chengfang Lv1, Limin
Li1, and Lingling Zhu1
1 Department of Hematology and 2 Central Laboratory, First Affiliated Hospital, Harbin Medical University, Harbin, China
The aim of this study was to determine the efficacy and safety of treatment of pediatric acute promyelocytic leukemia (APL) with single-agent arsenic trioxide (ATO). A total of 19 children ( 15 years of age) with newly diagnosed APL were treated with single-agent ATO for remission induction and postremission therapy. Seventeen of the children (89.5%) achieved complete hematologic remission, and 2 early deaths occurred from intracranial hemorrhage. ATO-induced leukocytosis was observed in 13 (68.4%) patients. Other ATO-related toxicities were minimal and transient. Postremission ATO therapy continued for 3 years; the most common side effect was ATO-induced neutropenia. With a median follow-up of 53 months (range, 23-76 months), the calculated 5-year overall survival and event-free survival were 83.9% and 72.7%, respectively, which are comparable with results achieved by the use of ATRA plus chemotherapy, which is the standard therapy for APL. No chronic arsenic toxicity or second malignancies were found during the follow-up period, and arsenic retention was not significant in patients off treatment more than 24 months. ATO resistance was observed in only 1 patient with a complex karyotype. The results indicate the high efficacy and safety of single-agent ATO regimens in the treatment of children with de novo APL.
| 已投稿到： |
|
|---|
